Google
CINGW — CINGULATE INC. WARRANTS
CINGW FAQ
What is CINGW's ROE?
CINGULATE INC. WARRANTS reports a Return on Equity (ROE) of -146.91%.
What is CINGW's dividend yield?
CINGULATE INC. WARRANTS offers a dividend yield of 0.00%.
What is CINGW's Deepscope Quality Score?
Deepscope rates CINGW's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CINGW?
Deepscope's AI Timing Score for CINGW is 0 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
|
USD 0.02
Price
-0.01
(-24.58%)
Day Change
|
|
|---|
CINGW, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
Last-year ROA is lower than last-2-years ROA.
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.02 |
| PBV / Sector |
N/A / N/A
|
| Earning Per Share | N/A |
| PE / Sector |
N/A / N/A
|
| PEG or PE/Growth / Sector |
N/A / N/A
|
| Average 1M Daily Value |
975.841445000000
|
| Average 1W Daily Value |
646.905300000000
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1901 West 47th Place, Kansas City, KS, United States, 66205
Phone: 913 942 2300
Website: https://www.cingulate.com
Sector: -
Description: Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
ME vs SECTOR
Click a bubble to view stock details · Bubble size represents market capitalization share
